Tags

Type your tag names separated by a space and hit enter

Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Diabetes Obes Metab. 2014 Jul; 16(7):588-601.DO

Abstract

Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once-daily GLP-1 RA for the treatment of T2DM. In persons with T2DM, lixisenatide 20 µg once-daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. Compared with the longer-acting GLP-1 RA liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (PPG) during a standardized test breakfast in persons with T2DM otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of T2DM in a series of phase III, randomized, placebo-controlled trials known as the GetGoal programme. Lixisenatide monotherapy or as add-on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, PPG and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once-daily, single-dose, add-on treatment to oral antidiabetic agents or basal insulin for the management of T2DM, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.

Authors+Show Affiliations

Department of Medicine, University of Perugia, Hospital S.M. della Misericordia, Perugia, Italy.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24373190

Citation

Bolli, G B., and D R. Owens. "Lixisenatide, a Novel GLP-1 Receptor Agonist: Efficacy, Safety and Clinical Implications for Type 2 Diabetes Mellitus." Diabetes, Obesity & Metabolism, vol. 16, no. 7, 2014, pp. 588-601.
Bolli GB, Owens DR. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16(7):588-601.
Bolli, G. B., & Owens, D. R. (2014). Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, Obesity & Metabolism, 16(7), 588-601. https://doi.org/10.1111/dom.12253
Bolli GB, Owens DR. Lixisenatide, a Novel GLP-1 Receptor Agonist: Efficacy, Safety and Clinical Implications for Type 2 Diabetes Mellitus. Diabetes Obes Metab. 2014;16(7):588-601. PubMed PMID: 24373190.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. AU - Bolli,G B, AU - Owens,D R, Y1 - 2014/01/20/ PY - 2013/02/14/received PY - 2013/04/15/revised PY - 2013/10/24/accepted PY - 2013/12/31/entrez PY - 2014/1/1/pubmed PY - 2015/3/10/medline KW - GLP-1 KW - diabetes mellitus SP - 588 EP - 601 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 16 IS - 7 N2 - Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to the development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once-daily GLP-1 RA for the treatment of T2DM. In persons with T2DM, lixisenatide 20 µg once-daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose-dependent manner. Compared with the longer-acting GLP-1 RA liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (PPG) during a standardized test breakfast in persons with T2DM otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of T2DM in a series of phase III, randomized, placebo-controlled trials known as the GetGoal programme. Lixisenatide monotherapy or as add-on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, PPG and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once-daily, single-dose, add-on treatment to oral antidiabetic agents or basal insulin for the management of T2DM, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/24373190/Lixisenatide_a_novel_GLP_1_receptor_agonist:_efficacy_safety_and_clinical_implications_for_type_2_diabetes_mellitus_ L2 - https://doi.org/10.1111/dom.12253 DB - PRIME DP - Unbound Medicine ER -